Orbital lymphoma: Radiotherapy outcome and complications

Scott L. Stafford, Timothy F. Kozelsky, James A. Garrity, Paul J. Kurtin, Jacqueline A. Leavitt, James A. Martenson, Thomas Matthew Habermann

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Background and purpose: Orbital non-Hodgkin's lymphomas (NHL) have traditionally been treated with radiation. Forty-eight patients presenting with orbital NHL were treated with radiation and were evaluated for local control, overall survival, cause-specific survival, and complications. Materials and methods: Forty-five patients had low-grade and 3 patients had intermediate-grade histologic findings. Orbit-only disease occurred in 22 patients, the conjunctiva in 16, both in five, and lacrimal gland only in five. Patient age ranged from 35 to 94 years (median, 68). Ann Arbor stages were cIEA (34), cIIEA (six), cIIIEA (two), and cIVEA (six). Radiation doses ranged between 15 and 53.8 Gy (median, 27.5 Gy). Results: Follow-up ranged from 0.14 to 18.23 years (median, 5.35). Median overall survival and cause-specific survival were 6.5 and 15.5 years, respectively. Patients with clinical stage I or II disease had significantly better overall and cause-specific survival than patients with stage III or IV disease. Ten-year relapse-free survival in 41 patients with stage I or II disease was 66%. However, there was continued downward pressure on relapse-free survival out to 18 years. One local failure occurred. Twenty-five patients sustained acute complications. There were 17 minor and four major late complications. All major late complications occurred with doses more than 35 Gy. Conclusions: Excellent local control with radiation doses ranging from 15 to 30 Gy is achieved. Patients with stage I or II disease have better overall and cause-specific survival than patients with stage III or IV disease. Late relapse occurs in sites other than the treated orbit, even in patients with early-stage disease. Doses 35 Gy or higher result in significant late complications and are therefore not indicated for patients with low-grade tumors.

Original languageEnglish (US)
Pages (from-to)139-144
Number of pages6
JournalRadiotherapy and Oncology
Volume59
Issue number2
DOIs
StatePublished - May 1 2001

Fingerprint

Radiotherapy
Survival
Radiation
Orbit
Recurrence
Orbital lymphoma
Non-Hodgkin's Lymphoma
Lacrimal Apparatus
Conjunctiva
Pressure

Keywords

  • Cataract
  • Complications
  • Orbital lymphoma
  • Radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology

Cite this

Stafford, S. L., Kozelsky, T. F., Garrity, J. A., Kurtin, P. J., Leavitt, J. A., Martenson, J. A., & Habermann, T. M. (2001). Orbital lymphoma: Radiotherapy outcome and complications. Radiotherapy and Oncology, 59(2), 139-144. https://doi.org/10.1016/S0167-8140(00)00328-5

Orbital lymphoma : Radiotherapy outcome and complications. / Stafford, Scott L.; Kozelsky, Timothy F.; Garrity, James A.; Kurtin, Paul J.; Leavitt, Jacqueline A.; Martenson, James A.; Habermann, Thomas Matthew.

In: Radiotherapy and Oncology, Vol. 59, No. 2, 01.05.2001, p. 139-144.

Research output: Contribution to journalArticle

Stafford, SL, Kozelsky, TF, Garrity, JA, Kurtin, PJ, Leavitt, JA, Martenson, JA & Habermann, TM 2001, 'Orbital lymphoma: Radiotherapy outcome and complications', Radiotherapy and Oncology, vol. 59, no. 2, pp. 139-144. https://doi.org/10.1016/S0167-8140(00)00328-5
Stafford SL, Kozelsky TF, Garrity JA, Kurtin PJ, Leavitt JA, Martenson JA et al. Orbital lymphoma: Radiotherapy outcome and complications. Radiotherapy and Oncology. 2001 May 1;59(2):139-144. https://doi.org/10.1016/S0167-8140(00)00328-5
Stafford, Scott L. ; Kozelsky, Timothy F. ; Garrity, James A. ; Kurtin, Paul J. ; Leavitt, Jacqueline A. ; Martenson, James A. ; Habermann, Thomas Matthew. / Orbital lymphoma : Radiotherapy outcome and complications. In: Radiotherapy and Oncology. 2001 ; Vol. 59, No. 2. pp. 139-144.
@article{fc77e48e7095470f88f0545fb6e2bb00,
title = "Orbital lymphoma: Radiotherapy outcome and complications",
abstract = "Background and purpose: Orbital non-Hodgkin's lymphomas (NHL) have traditionally been treated with radiation. Forty-eight patients presenting with orbital NHL were treated with radiation and were evaluated for local control, overall survival, cause-specific survival, and complications. Materials and methods: Forty-five patients had low-grade and 3 patients had intermediate-grade histologic findings. Orbit-only disease occurred in 22 patients, the conjunctiva in 16, both in five, and lacrimal gland only in five. Patient age ranged from 35 to 94 years (median, 68). Ann Arbor stages were cIEA (34), cIIEA (six), cIIIEA (two), and cIVEA (six). Radiation doses ranged between 15 and 53.8 Gy (median, 27.5 Gy). Results: Follow-up ranged from 0.14 to 18.23 years (median, 5.35). Median overall survival and cause-specific survival were 6.5 and 15.5 years, respectively. Patients with clinical stage I or II disease had significantly better overall and cause-specific survival than patients with stage III or IV disease. Ten-year relapse-free survival in 41 patients with stage I or II disease was 66{\%}. However, there was continued downward pressure on relapse-free survival out to 18 years. One local failure occurred. Twenty-five patients sustained acute complications. There were 17 minor and four major late complications. All major late complications occurred with doses more than 35 Gy. Conclusions: Excellent local control with radiation doses ranging from 15 to 30 Gy is achieved. Patients with stage I or II disease have better overall and cause-specific survival than patients with stage III or IV disease. Late relapse occurs in sites other than the treated orbit, even in patients with early-stage disease. Doses 35 Gy or higher result in significant late complications and are therefore not indicated for patients with low-grade tumors.",
keywords = "Cataract, Complications, Orbital lymphoma, Radiation therapy",
author = "Stafford, {Scott L.} and Kozelsky, {Timothy F.} and Garrity, {James A.} and Kurtin, {Paul J.} and Leavitt, {Jacqueline A.} and Martenson, {James A.} and Habermann, {Thomas Matthew}",
year = "2001",
month = "5",
day = "1",
doi = "10.1016/S0167-8140(00)00328-5",
language = "English (US)",
volume = "59",
pages = "139--144",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Orbital lymphoma

T2 - Radiotherapy outcome and complications

AU - Stafford, Scott L.

AU - Kozelsky, Timothy F.

AU - Garrity, James A.

AU - Kurtin, Paul J.

AU - Leavitt, Jacqueline A.

AU - Martenson, James A.

AU - Habermann, Thomas Matthew

PY - 2001/5/1

Y1 - 2001/5/1

N2 - Background and purpose: Orbital non-Hodgkin's lymphomas (NHL) have traditionally been treated with radiation. Forty-eight patients presenting with orbital NHL were treated with radiation and were evaluated for local control, overall survival, cause-specific survival, and complications. Materials and methods: Forty-five patients had low-grade and 3 patients had intermediate-grade histologic findings. Orbit-only disease occurred in 22 patients, the conjunctiva in 16, both in five, and lacrimal gland only in five. Patient age ranged from 35 to 94 years (median, 68). Ann Arbor stages were cIEA (34), cIIEA (six), cIIIEA (two), and cIVEA (six). Radiation doses ranged between 15 and 53.8 Gy (median, 27.5 Gy). Results: Follow-up ranged from 0.14 to 18.23 years (median, 5.35). Median overall survival and cause-specific survival were 6.5 and 15.5 years, respectively. Patients with clinical stage I or II disease had significantly better overall and cause-specific survival than patients with stage III or IV disease. Ten-year relapse-free survival in 41 patients with stage I or II disease was 66%. However, there was continued downward pressure on relapse-free survival out to 18 years. One local failure occurred. Twenty-five patients sustained acute complications. There were 17 minor and four major late complications. All major late complications occurred with doses more than 35 Gy. Conclusions: Excellent local control with radiation doses ranging from 15 to 30 Gy is achieved. Patients with stage I or II disease have better overall and cause-specific survival than patients with stage III or IV disease. Late relapse occurs in sites other than the treated orbit, even in patients with early-stage disease. Doses 35 Gy or higher result in significant late complications and are therefore not indicated for patients with low-grade tumors.

AB - Background and purpose: Orbital non-Hodgkin's lymphomas (NHL) have traditionally been treated with radiation. Forty-eight patients presenting with orbital NHL were treated with radiation and were evaluated for local control, overall survival, cause-specific survival, and complications. Materials and methods: Forty-five patients had low-grade and 3 patients had intermediate-grade histologic findings. Orbit-only disease occurred in 22 patients, the conjunctiva in 16, both in five, and lacrimal gland only in five. Patient age ranged from 35 to 94 years (median, 68). Ann Arbor stages were cIEA (34), cIIEA (six), cIIIEA (two), and cIVEA (six). Radiation doses ranged between 15 and 53.8 Gy (median, 27.5 Gy). Results: Follow-up ranged from 0.14 to 18.23 years (median, 5.35). Median overall survival and cause-specific survival were 6.5 and 15.5 years, respectively. Patients with clinical stage I or II disease had significantly better overall and cause-specific survival than patients with stage III or IV disease. Ten-year relapse-free survival in 41 patients with stage I or II disease was 66%. However, there was continued downward pressure on relapse-free survival out to 18 years. One local failure occurred. Twenty-five patients sustained acute complications. There were 17 minor and four major late complications. All major late complications occurred with doses more than 35 Gy. Conclusions: Excellent local control with radiation doses ranging from 15 to 30 Gy is achieved. Patients with stage I or II disease have better overall and cause-specific survival than patients with stage III or IV disease. Late relapse occurs in sites other than the treated orbit, even in patients with early-stage disease. Doses 35 Gy or higher result in significant late complications and are therefore not indicated for patients with low-grade tumors.

KW - Cataract

KW - Complications

KW - Orbital lymphoma

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0035336821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035336821&partnerID=8YFLogxK

U2 - 10.1016/S0167-8140(00)00328-5

DO - 10.1016/S0167-8140(00)00328-5

M3 - Article

C2 - 11325441

AN - SCOPUS:0035336821

VL - 59

SP - 139

EP - 144

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 2

ER -